A Phase 3 interventional study of STN1012600 ophthalmic solution 0.002% and Latanoprost ophthalmic solution 0.005% in Primary Open Angle Glaucoma, Ocular Hypertension, sponsored by Santen Pharmaceutical Co., Ltd.. Completed at 44 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-05.
Sponsored by Santen Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd. — 1 open to participants now, 2 under way, 1 of them phase 3. Glaucoma, Open-Angle · Santen Pharmaceutical Co., Ltd..
Among the 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd., this one is the 8th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2022, is one of 17 in phase 3, and was the 34th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →1 of the 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd. is open now, in 8 countries. Recruiting first, the newest first:
Santen SAS · Sites in Austria, Belgium, Germany and 5 more countries
Ages 18–85
By country, each count listing its studies:
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 18 · Phase 4 1
First in 2005; this study’s year is marked. 3 started in 2022.
This study's enrollment of 325 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 165 across the 31 interventional studies, 196 across the 4 observational. Of the 33 that completed or were terminated, 14 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
Santen Pharmaceutical Co., Ltd. is the lead sponsor of 30 studies on the registry; 1 is open to participants now.
1 of the studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07235592Santen SASPRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To investigate whether the IOP lowering efficacy of STN1012600 ophthalmic solution 0.002% is non-inferior to that of latanoprost 0.005% in subjects with POAG or OHT after treatment for 4 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: STN1012600 ophthalmic solution 0.002%
Drug: Latanoprost ophthalmic solution 0.005%
1 drop STN1012600 ophthalmic solution 0.002% once daily for 3 months
1 drop Latanoprost ophthalmic solution 0.005% once daily for 3 months
Change from baseline in mean diurnal intraocular pressure
Change from baseline in mean diurnal intraocular pressure at Week 4
Time frame: 4 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2022 to primary completion in Apr 2023, 8 months.
Of 47 industry-sponsored phase 3 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's 8 months is below that.
Counting every sponsor, half of 49 studies reached it within 26 months; a quarter within 12 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sepetaprost
Santen Pharmaceutical Co., Ltd. →